drugset / Trial / NCT00962923

Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)

NCT00962923

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will explore safety and efficacy of allogeneic mesenchymal stem cells transplantation (MSCT) to treat patients with diagnosis of systemic sclerosis(SSc) who have been resistant to multiple standard treatments. The underlying hypothesis is that the SSc condition is caused by an abnormal immune homeostasis that can be restored by MSCT.

Timeline

Start
2009-08
Primary completion
2010-12
Completion
2011-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous

Indications